A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006553/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate the efficacy and safety of BAX 855 in severe
hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing
elective surgical or other invasive procedures.
提供机构：
Vivli
创建时间：
2021-01-19
